Vyome (HIND) vs IN8bio (INAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IN8bio (INAB) has outperformed Vyome (HIND) over the past year, losing 42.7% versus a loss of 65.4%. Over five years, INAB leads with a -99.2% price change compared with -100.0% for HIND. Vyome is the larger company by market cap ($14.2 million vs $13.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HIND | INAB |
|---|---|---|
| Share price | $2.03 | $1.38 |
| Market cap | $14.25M | $13.60M |
| 1-day change | -0.49% | -1.43% |
| YTD return | -40.99% | -41.03% |
| 1-year return | -65.42% | -42.74% |
| 5-year return | -100.00% | -99.23% |
| P/E ratio (TTM) | 1.14 | — |
| EPS (TTM) | $1.78 | $-1.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.56 | $2.73 |
| 52-week low | $1.75 | $0.88 |
| Distance from 52-week high | -69.05% | -49.45% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +334.98% | +407.25% |
| Average volume | 13.32K | 58.36K |
| Shares outstanding | 7.02M | 9.86M |
| Employees | 9 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed HIND by 22.7 percentage points over the past year.
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
HIND vs INAB FAQ
Which is bigger, Vyome or IN8bio?
Vyome (HIND) is larger, with a market capitalization of $14.25M compared with $13.60M for IN8bio (INAB).
Which stock has performed better over the past year, HIND or INAB?
INAB returned -42.74% over the past 12 months, compared with -65.42% for HIND (price return, excluding dividends). Past performance does not predict future results.
Are Vyome and IN8bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Vyome and Biotechnology: Biological Products (No Diagnostic Substances) for IN8bio.